CJC-1295 with DAC 2mg

Researched Benefits & Focus Areas – CJC-1295 with DAC

1. Growth Hormone (GH) Secretion Research

CJC-1295 with DAC has been studied for:

• Stimulation of endogenous growth hormone release
• Investigation of pituitary signalling pathways
• Modelling hormonal secretion patterns

Reference basis: Derived from preclinical and clinical research examining GHRH analogues and their effect on growth hormone release.

2. IGF-1 Pathway & Endocrine Regulation

Research has explored its role in:

• Increasing IGF-1 levels in experimental models
• Studying growth factor signalling cascades
• Analysing endocrine system regulation

Reference basis: Based on endocrinology studies investigating GH/IGF-1 axis modulation via GHRH analogues.

3. Extended Half-Life & DAC Technology

The DAC component enables:

• Prolonged peptide stability in circulation (research models)
• Reduced frequency of administration in experimental protocols
• Improved binding to plasma proteins (e.g. albumin)

Reference basis: Supported by pharmacokinetic research into Drug Affinity Complex (DAC) technology and peptide stabilisation mechanisms.

4. Hormonal Pulsatility & Regulation Studies

CJC-1295 with DAC is used in:

• Research into natural hormone release patterns
• Analysis of pituitary gland signalling behaviour
• Studies of long-term hormonal modulation

Reference basis: Derived from clinical and experimental research on hormonal pulsatility and GHRH analogue behaviour.

Disclaimer: These are research-based findings only. This product is not intended for human use or consumption.

Researched Risks & Considerations – CJC-1295 with DAC

1. Hormonal System Disruption

Due to its mechanism:

• May alter natural hormone balance in research models
• Potential for overstimulation of GH pathways

Reference basis: Based on endocrine research into growth hormone regulation and feedback mechanisms.

2. Prolonged Exposure Effects

With extended half-life:

• Increased duration of biological activity
• Potential for accumulated signalling effects

Reference basis: Derived from pharmacokinetic studies on long-acting peptide analogues and sustained receptor activation.

3. Off-Target Endocrine Interaction

• May influence other hormonal pathways
• Potential for system-wide endocrine effects

Reference basis: Based on studies examining interconnected hormonal signalling systems and receptor cross-talk.

4. Limited Long-Term Research

• Limited long-term safety data
• Primarily studied in controlled experimental settings

Reference basis: Reflects the current research status of long-acting GHRH analogues.

Disclaimer: These risks are based on available research data only. This product is strictly a research peptide and not for human consumption.

Additional information